15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 3 firms covering Mednax Inc, 0 rate it Buy or better, 3 sit at Hold, and 0 rate it Sell or worse, a hold consensus. Targets are tightly clustered, $25.00 to $28.00, so the covering firms are broadly aligned. The average target of $26.50 sits 1% below the current $26.86. The rating mix has stayed broadly stable, with Buy-side ratings easing from 1 to 0 over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.67 next quarter toward $2.36 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 ratings
Hold
Strong Buy00%
Buy00%
Hold3100%
Sell00%
Strong Sell00%
Based on 3 analysts giving stock ratings to Mednax Inc.
As of Jul, 0 of 3 firms rate MD a Buy (3 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
MD EPS & revenue forecast
EPS · NEXT QUARTER
$0.67
Range $0.62 – $0.72 · 7 analysts · -0% YoY
Next period, 7 analysts expect Mednax Inc to earn $0.67 a share (range $0.62 – $0.72), versus $0.67 a year earlier. Full-year consensus is $2.28, growing to $2.36 the year after.
REVENUE · NEXT QUARTER
$492.2M
Range $483.7M – $496.5M · 7 analysts · -0% YoY
Revenue is expected to reach $492.2M (range $483.7M – $496.5M), -0.1% year-over-year. Full-year consensus is $1.9B, rising to $2.0B next year.
Top analysts covering Mednax Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on MD.
#1
DM
David Macdonald
Truist Securities · Rank #67
Hold
$28.00+4.2% to target
Overall win rate
51%
+ Follow
#2
AR
A.J. Rice
UBS
Hold
$25.00-6.9% to target
Coverage
—
+ Follow
#3
JS
Jack Slevin
Jefferies
Buy
$27.00+0.5% to target
Coverage
—
+ Follow
#4
PC
Pito Chickering
Deutsche Bank
Hold
$19.00-29.3% to target
Coverage
—
+ Follow
#5
Whit Mayo
Leerink Partners
Hold
$17.00-36.7% to target
Coverage
—
+ Follow
MD stock forecast FAQ
What is MD's average 12-month price target?+
The 2 analysts with a live target average $26.50 for Mednax Inc over the next 12 months, ranging from a $28.00 high to a $25.00 low.
Is MD stock a Buy, Sell or Hold right now?+
The current consensus is Hold. Of the 3 analyst ratings, 0 are Buy or Strong Buy, 3 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for MD?+
The Street-high target is $28.00 (Truist Securities), and the Street-low is $25.00 (UBS). The average of all 2 active targets is $26.50.
How many Wall Street analysts cover MD?+
3 analysts have an active rating on Mednax Inc, and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering MD?+
Among analysts who currently cover MD, David Macdonald of Truist Securities has the strongest overall Quantellect track record (Rank #67). Their current call is Hold with a $28.00 target.
What is Mednax Inc's projected EPS for next quarter?+
The consensus estimate is $0.67 per share (range $0.62 – $0.72) across 7 analysts. Full-year EPS is projected at $2.28, rising to $2.36 the following year.
How much revenue is Mednax Inc expected to report next quarter?+
Consensus revenue is $492.2M (range $483.7M – $496.5M). Full-year revenue is projected at $1.9B, growing to $2.0B next year.
Have analysts been upgrading or downgrading MD lately?+
As of Jul, 0 of 3 firms rate MD a Buy (3 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their MD calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
